Search Results

You are looking at 121 - 130 of 196 items for :

  • Refine by Access: All x
Clear All
Full access

Saurabh Rajguru and Brad S. Kahl

). Toxicity was not insignificant, with 17% and 12% of patients hospitalized for grade 3 and 4 adverse events (AEs), respectively—mostly neutropenic fever. The 4-year PFS and OS rates were 73% and 81%, respectively. 10 An update after 6 years of follow

Full access

Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Andrew Rowland, Ashley M. Hopkins, and Michael J. Sorich

other cancer types or ICIs. Third, the data had investigator-reported AEs and there was no external validation/confirmation of AEs. Finally, the irAEs analyzed were organ-specific, and did not include constitutional symptoms such as fatigue and fever

Full access

David D. Stenehjem, Frederick Albright, Kuan-Ling Kuo, Karina Raimundo, Hillevi Bauer, Paul J. Shami, Michael W. Deininger, Lei Chen, and Diana I. Brixner

myalgias, fatigue, fever, edema, and headache. Among patients experiencing an ADE, 10 (32%) had a dose reduction. The median time to dose reduction was 52 days, and the new median dose was 300 mg/d. A total of 6 patients (19%) discontinued imatinib because

Full access

P. Connor Johnson, Caron Jacobson, Alisha Yi, Anna Saucier, Tejaswini M. Dhawale, Ashley Nelson, Mitchell W. Lavoie, Mathew J. Reynolds, Carlisle E.W. Topping, Matthew J. Frigault, and Areej El-Jawahri

determine reasons for hospital readmissions. 12 In the schema for our study, these reasons included symptoms, fever without a source, febrile neutropenia, confirmed infection, dehydration/electrolyte abnormalities, planned hospitalization

Full access

Meena A. Prasad and Laura M. Kulik

.4% vs 61.5%; P =.0493). 30 Table 2 Factors to Consider Before RFA Unfortunately, more than 50% of patients undergoing TACE develop symptoms of postembolization syndrome, consisting of abdominal pain, fever, nausea, and vomiting. In

Full access

Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Robin M. Lally, Terry S. Langbaum, Allison L. McDonough, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass

avoidance of zoonosis, travel precautions, and gardening precautions. 121 – 126 Contact with pets did not increase the risk of fever, bacteremia, pneumonia, and gastroenteritis in children with acute myeloid leukemia, 127 and the panel believes that

Full access

Ndiya Ogba, Nicole M. Arwood, Nancy L. Bartlett, Mara Bloom, Patrick Brown, Christine Brown, Elizabeth Lihua Budde, Robert Carlson, Stephanie Farnia, Terry J. Fry, Morgan Garber, Rebecca A. Gardner, Lauren Gurschick, Patricia Kropf, Jeff J. Reitan, Craig Sauter, Bijal Shah, Elizabeth J. Shpall, and Steven T. Rosen

duration of 1 week. The first sign of CRS is usually fever, which can progress to hypotension and/or hypoxia; other signs and symptoms may include arrhythmias, coagulopathies, tachycardia, and other organ toxicities. 62 , 63 Management strategies have been

Full access

Dawn Goetz

regularly scheduled treatment, they must undergo an additional leukapheresis procedure. 21 , 22 The most common adverse events are chills, fatigue, fever, dyspnea, back pain, nausea, joint ache, and headache, most of which are mild and transient. 14 , 21

Full access

Damon Reed, Ragini Kudchadkar, Jonathan S. Zager, Vernon K. Sondak, and Jane L. Messina

pediatric population are used to justify interferon use in the pediatric melanoma population. In adults, the side-effect profile deters many patients from receiving interferon: toxicity such as fevers, fatigue, myalgias/arthralgias, and depression limit

Full access

Ryan D. Gentzler and Jyoti D. Patel

factors that preclude the use of bevacizumab, and the desire to avoid alopecia and neutropenic fever. For most patients with NS-NSCLC, optimal first-line treatment is a combination of a platinum drug with pemetrexed alone, pemetrexed and bevacizumab, or